EGAPP ‘Discourages’ CYP450 Testing To Choose SSRIs for Depression

The findings “don't mean that CYP450 testing is not potentially useful,” but “rather there is currently insufficient evidence either for or against the use of CYP450 testing in patients beginning SSRI treatment for depression,” the working group states.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.

Related Stories